Sana Khan

Sana Khan

Auto-generated profile, based on publicly available information

Sana Khan

Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
SSSadat Shafi
Sadat Shafi
FAFaraha Ahmed
Faraha Ahmed
FAFaraha Ahmed
Faraha Ahmed
SASyed Sufiyan Ahmad
Syed Sufiyan Ahmad
SKSana Khan
Sana Khan
ANAbul Kalam Najmi
Abul Kalam Najmi
Considerable advancements have been made in breast cancer therapeutics in the past few decades. However, the advent of chemo-resistance and adverse drug reactions coupled with tumor metastasis and recurrence posed a serious threat to combat this lethal disease. Novel anti-cancer agents, as well as new therapeutic strategies, are needed to complement conventional breast cancer therapies. The quest for developing novel anti-cancer drugs caused an upsurge in exploring and harnessing natural compounds, especially phytochemicals. Various research groups have explored and documented the anti-cancer potential of wide variety of phytochemical groups including flavonoids (curcumin, kaempferol, myricetin, quercetin, naringenin, apigenin, genistein epigallocatechin gallate), stilbenes (resveratrol), carotenoids (crocin, lycopene, lutein), and anthraquinone (Emodin). However, low chemical stability, poor water solubility, and short systemic half-life impede their clinical utility. The implication of nano-technological approaches to decode the pharmacokinetic challenges associated with phytochemical usage, as well as selective drug targeting, have markedly enhanced the pre-clinical anti-cancer activity, thus aiding in their clinical translation. This review documented the recent advances in utilizing phytochemicals for breast cancer prevention and lipidbased nanotechnological approaches for circumventing their pharmacokinetic concerns to enhance their systemic availability, cytotoxicity, and targeted delivery against breast cancer alone as well as in combination with conventional therapeutic agents.

1 February 2016 in Fertility and Sterility
Verified
Journal Article
Open access
PDF file
RJRoohi Jeelani
Roohi Jeelani
FSFaten Shaeib
Faten Shaeib
MTMili Thakur
Mili Thakur
SKSana Khan
Sana Khan
HAHusam M. Abu-Soud
Husam M. Abu-Soud